IN THE UNITED STATES DISTRICT COURT

KELLYN CLAY,
  Plaintiff,

v.

UNITED STATES OF AMERICA,
by and through its agencies including but not limited to
the Central Intelligence Agency (CIA), Department of Defense (DoD),
and Department of Justice (DOJ),

and

WILLIAM ALTON CLAY,
individually and in his capacity as executor of the Estate of Eugenia Clay Head,

and

PALANTIR TECHNOLOGIES INC.,
a private defense contractor headquartered in Denver, Colorado,

and

JOHN DOE CONTRACTING AGENCIES AND AFFILIATES,
whose names and identities are presently unknown,

and

AMAZON.COM, INC.,
a multinational e-commerce corporation headquartered in Seattle, Washington,

and

REV.COM, INC.,
a transcription and captioning services company headquartered in Austin, Texas,

and

PAPERBOY MARKETING,
a flyer distribution company operating in the Twin Cities under successive ownership during the period of Plaintiff’s employment,

and

ELLIE FAMILY SERVICES, n/k/a ELLIE MENTAL HEALTH, a private mental health services corporation headquartered in Mendota Heights, Minnesota,
  Defendants.

⸻

PLAINTIFF’S THIRTEENTH SET OF DISCOVERY REQUESTS TO DEFENDANT PALANTIR TECHNOLOGIES

Plaintiff: Kellyn Clay
Defendant: Palantir Technologies Inc.
Subject Matter: Operation Warp Speed Contracts and Vaccine Lot-Level Anomaly Detection

⸻

INTERROGATORIES
	1.	Identify all contracts, task orders, or agreements between Palantir and the U.S. Department of Health and Human Services (including BARDA, NIH, CDC, FDA) in connection with Operation Warp Speed.
	2.	Identify all contracts, task orders, or agreements between Palantir and the U.S. Department of Defense in connection with Operation Warp Speed.
	3.	Identify all roles, functions, or responsibilities Palantir undertook in Operation Warp Speed concerning vaccine safety, distribution, or anomaly detection.
	4.	Identify all Palantir personnel, contractors, or teams assigned to Operation Warp Speed contracts.
	5.	Identify whether Palantir’s systems ingested, flagged, or analyzed data concerning the two Moderna vaccine lot numbers administered to Plaintiff.
	6.	Identify all government agencies or third-party contractors to whom Palantir provided data, reports, or dashboards concerning Plaintiff’s Moderna vaccine lot numbers.

⸻

REQUESTS FOR PRODUCTION
	1.	Produce all contracts, task orders, or agreements between Palantir and HHS concerning Operation Warp Speed.
	2.	Produce all contracts, task orders, or agreements between Palantir and DoD concerning Operation Warp Speed.
	3.	Produce all reports, dashboards, or analytic outputs generated by Palantir under Operation Warp Speed that reference vaccine lot numbers, adverse events, or anomaly detection.
	4.	Produce all internal Palantir communications, memoranda, or analyses discussing vaccine lot-level data anomalies.
	5.	Produce all records linking Plaintiff’s Moderna vaccine lot numbers to Palantir’s Operation Warp Speed systems.
	6.	Produce all records showing whether Palantir flagged Plaintiff’s doses as contaminated, anomalous, or otherwise significant in its anomaly detection systems.

⸻

REQUESTS FOR ADMISSION
	1.	Admit that Palantir contracted with HHS in connection with Operation Warp Speed.
	2.	Admit that Palantir contracted with DoD in connection with Operation Warp Speed.
	3.	Admit that Palantir’s systems ingested and analyzed vaccine lot-level data under Operation Warp Speed.
	4.	Admit that Palantir flagged certain vaccine lot numbers as anomalous or contaminated.
	5.	Admit that Palantir ingested and analyzed data concerning the two Moderna vaccine lot numbers administered to Plaintiff.
	6.	Admit that Palantir has not disclosed to Plaintiff the scope of its analysis of Plaintiff’s vaccine lot numbers.
    7.  Admit that Palantir ingested data concerning the two Moderna vaccine lot numbers administered to Plaintiff in 2021.
	8.	Admit that Palantir tracked, monitored, or otherwise processed adverse event data associated with these lot numbers.
	9.	Admit that Palantir flagged one or both of Plaintiff’s Moderna lot numbers as anomalous.
	10.	Admit that Palantir flagged one or both of Plaintiff’s Moderna lot numbers as contaminated or potentially contaminated.
	11.	Admit that Palantir communicated internally about anomaly or contamination flags linked to Plaintiff’s Moderna lot numbers.
	12.	Admit that Palantir communicated with one or more federal agencies (including HHS, CDC, FDA, or DoD) concerning anomaly or contamination flags for Plaintiff’s Moderna lot numbers.
	13.	Admit that Palantir linked Plaintiff’s adverse health outcomes following vaccination to the lot numbers administered.
	14.	Admit that Palantir monetized or modeled anomaly data concerning Plaintiff’s Moderna lot numbers in behavioral futures markets.
	15.	Admit that Palantir has not disclosed to Plaintiff the existence of contamination or anomaly flags related to Plaintiff’s Moderna lot numbers.

